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OBJECTIVE We examined long-term outcomes of patients with in-stent restenosis (ISR) who underwent
different percutaneous interventions at the discretion of individual operators: balloon
angioplasty (BA), repeat stent or rotational atherectomy (RA). We also examined long-term
outcomes of patients with ISR who underwent coronary artery bypass surgery (CABG).
BACKGROUND In-stent restenosis remains a challenging problem, and its optimal management is still
unknown.
METHODS Symptomatic patients (n 5 510) with ISR were identified using cardiac catheterization
laboratory data. Management for ISR included BA (169 patients), repeat stenting (117
patients), RA (107 patients) or CABG (117 patients). Clinical outcome events of interest
included death, myocardial infarction, target vessel revascularization (TVR) and a combined
end point of these major adverse cardiovascular events (MACE). Mean follow-up was 19 6
12 months (range 5 6 to 61 months).
RESULTS Patients with ISR treated with repeat stent had significantly larger average post-procedure
minimal lumen diameter compared with BA or RA (3.3 6 0.4 mm vs. 3.0 6 0.4 vs. 2.9 6
0.5, respectively, p , 0.05). Incidence of TVR and MACE were similar in the BA, stent and
RA groups (39%, 40%, 33% for TVR and 43%, 40%, 33% for MACE, p 5 NS). Patients
with diabetes who underwent RA had similar outcomes as patients without diabetes, while
patients with diabetes who underwent BA or stent had worse outcomes than patients without
diabetes. Patients who underwent CABG for ISR, mainly because of the presence of
multivessel disease, had significantly better outcomes than any percutaneous treatment (8%
for TVR and 23% for MACE).
CONCLUSIONS In this large cohort of patients with ISR and in the subset of patients without diabetes,
long-term outcomes were similar in the BA, repeat stent and RA groups. Tissue debulking
with RA yielded better results only in diabetic patients. Bypass surgery for patients with
multivessel disease and ISR provided the best outcomes. (J Am Coll Cardiol 2001;37:
1877–82) © 2001 by the American College of Cardiology
Intracoronary stenting has been shown to have superior
short- and long-term outcomes compared with conven-
tional balloon angioplasty (1–3). Consequently, stenting is
the procedure of choice in most percutaneous coronary
interventions. However, angiographic and clinical restenosis
after stenting develops in 15% to 45% of the cases and
constitutes a major limitation to the effectiveness of this
technique (1–4). Treatment of in-stent restenosis (ISR) has,
therefore, become an important clinical problem. Several
studies have shown variable results using balloon angioplasty
(BA) alone (5–10), repeat stenting (11,12), rotational
atherectomy (RA) (13–16) or directional atherectomy
(17,18), excimer laser angioplasty (19,20) and, more re-
cently, intracoronary radiation therapy (21–23). Other stud-
ies have compared these different techniques (24–31), and it
is still unclear which one, if any, will provide the most
favorable outcomes. The goal of this study was to compare
the long-term outcomes of symptomatic patients with
angiographically proven ISR who underwent either BA,
repeat stenting or RA or those patients who underwent
coronary artery bypass graft surgery (CABG).
METHODS
Patients. We reviewed the cardiac catheterization labora-
tory records from both Memorial Hermann Hospital and
St. Luke’s Episcopal Hospital in Houston, Texas. Between
January 1995 and July 1999, a total of 630 consecutive
patients with no prior history of CABG underwent coro-
nary angiography for chest pain syndromes and had angio-
graphically documented first occurrence of ISR of native
coronary vessels ($70% diameter stenosis at the stented
region). Of those, 120 patients received medical treatment
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only and were excluded from our study. The remaining
patients (n 5 510) underwent revascularization for in-stent
restenosis, including BA (169 patients), repeat stenting
(117 patients), RA (107 patients) or CABG (117 pa-
tients). The choice of revascularization procedure was at
the discretion of the operator, and all procedures were
done according to standard techniques. None of the study
patients received medications or radiation specifically to
prevent restenosis.
Demographic and clinical characteristics. At both in-
stitutions, demographic and clinical characteristics were
recorded on standard forms. Angiographic and proce-
dural data were recorded by trained cardiac catheteriza-
tion laboratory personnel. Postprocedural events were
monitored and recorded using standard protocols in each
hospital.
Follow-up. Information was collected primarily using a
mailed standardized questionnaire. Additional information
was obtained using telephone contacts or review of medical
records during outpatient visits and hospitalizations.
Clinical end points. Clinical end points of interest in-
cluded death from any cause, target vessel revascularization
(TVR), including percutaneous interventions or surgical
revascularization, myocardial infarction (MI) or angina
necessitating hospitalization accompanied with documented
ischemia on a stress test. A combined end point of these was
termed major adverse cardiovascular events (MACE). Pa-
tients were not re-entered into the study after reaching an
initial end point.
STATISTICAL ANALYSIS
Continuous data are presented as mean 6 SD, and discrete
data are presented as frequencies. Continuous data were
compared using analysis of variance, and frequencies were
compared using the chi-square or Fischer exact tests. To
account for different duration of follow-up, the incidence of
event-free survival was compared among four groups. A
multivariate analysis was performed to identify the predic-
tors of adverse cardiovascular events in a model that in-
cluded age, gender, hypertension, diabetes, hypercholester-
olemia, smoking status, lesion location, lesion type and
length and mode of intervention. A p value of ,0.05 was
considered to be significant.
RESULTS
Demographic and clinical characteristics. The demo-
graphic and clinical characteristics of the 510 patients
included in the analysis are shown in Table 1. None of the
values were significantly different.
Angiographic characteristics. As depicted in Table 2,
patients who underwent repeat stenting had left anterior
descending artery (LAD) lesions treated less often com-
pared with patients with treated with BA, RA or CABG.
They also had a shorter mean ISR lesion length and larger
mean postintervention minimal lumen diameter (MLD)
when compared with patients receiving BA or RA treat-
ment. Multivessel disease was present in 20% to 25% of
patients who had percutaneous interventions for ISR but
was present in 85% of patients who received CABG for
ISR.
Clinical end points. Adequate follow-up was obtained in
490 patients (96%), and mean follow-up duration was 19 6
12 months (range 6 to 61 months). The incidence of
different clinical end points in all four groups is shown in
Table 3. No significant differences were seen in the inci-
dence of TVR (including percutaneous interventions) or
MACE between patients who underwent BA or repeat
stent treatment (39% vs. 40% for TVR and 43% vs. 40% for
MACE). On the other hand, patients who underwent RA
Abbreviations and Acronyms
BA 5 balloon angioplasty
CABG 5 coronary artery bypass graft surgery
ISR 5 in-stent restenosis
LAD 5 left anterior descending artery
MACE 5 major adverse cardiovascular events
MI 5 myocardial infarction
MLD 5 minimal lumen diameter
RA 5 rotational atherectomy
TVR 5 target vessel revascularization
Table 1. Demographic and Clinical Characteristics of Patients With In-Stent Restenosis
According to Treatment Group
Balloon
Angioplasty
(n 5 169)
Stent
(n 5 117)
Rotational
Atherectomy
(n 5 107)
CABG
(n 5 117)
Age (yr) 61 6 12 63 6 13 60 6 10 64 6 12
Women (%) 34 39 35 25
Diabetes (%) 25 29 36 32
Hypertension (%) 79 79 76 76
Hypercholesterolemia (%) 64 62 77 64
Smoker (%) 56 53 55 60
Prior CHF (%) 13 14 16 12
Prior MI (%) 45 39 46 51
CABG 5 coronary artery bypass graft surgery; CHF 5 congestive heart failure; MI 5 myocardial infarction.
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had a lower incidence of TVR and MACE when compared
with patients treated with BA and repeat stent, although it
did not reach statistical significance. Patients who under-
went CABG had a significantly lower incidence of TVR
(8%) and MACE (23%) compared with patients who
underwent a percutaneous intervention. No significant dif-
ferences were seen in the incidence of death or angina/MI
among all four groups. The incidence of two-year event-free
survival was also compared among four groups. As seen in
Table 4, BA, stent and RA yielded similar outcomes. On
the other hand, TVR-free and MACE-free survival were
higher in the CABG group (p 5 0.01 for TVR and 0.06 for
MACE). After controlling for baseline variables, CABG,
but not BA, stent or RA, was independently associated with
lower incidences of TVR and MACE.
Effect of diabetes mellitus. Patients were grouped accord-
ing to their diabetic status, and clinical outcome was
assessed in different treatment groups. As shown in Table 5,
the incidence of TVR and MACE was the same in patients
with diabetes who underwent BA or repeat stent and was
significantly higher than it was in patients without diabetes.
Patients with diabetes who underwent RA had a lower
incidence of TVR and MACE than patients with diabetes
who underwent BA or repeat stenting, and their outcome
was similar to patients without diabetes who underwent
percutaneous interventions. There were no significant dif-
ferences in the incidence of TVR or MACE in patients
without diabetes regardless of the percutaneous intervention
used. Coronary artery bypass graft surgery was superior to
percutaneous interventions in both patients with and with-
out diabetes. Mortality was similar in patients with and
without diabetes regardless of which intervention was used.
DISCUSSION
To our knowledge, this is one of the largest studies that
compare the long-term outcomes of patients who under-
went BA, repeat stent or RA for ISR. This is also the first
study that assesses the long-term outcomes of surgical
revascularization for this problem.
Despite a better procedural outcome in the repeat stent
group with a larger postprocedure MLD, the long-term
outcomes of these patients were similar to those who
underwent BA alone. Patients who underwent debulking
with RA had a better long-term outcome than patients
undergoing BA or repeat stent, although with the small
number of patients, the difference did not reach statistical
significance. Patients with diabetes who underwent RA had
similar outcomes as patients without diabetes, while patients
with diabetes who underwent BA or repeat stenting had
worse outcomes than patients without diabetes. Patients
who underwent CABG for ISR (mainly because of the
presence of multivessel disease) had the best outcomes of all
groups.
Stenting versus PTCA. Several studies have shown that
stenting for de novo lesions provides better short- and
long-term outcomes compared with BA alone (1–3). In
the BElgian NEtherlands Stent (BENESTENT) study
(1), for example, the mean postprocedure MLD was
larger in the stent group compared with the BA group,
and, at seven month follow-up, 20% of patients in the
stent group had undergone TVR compared with 30% in
the BA group. In a different study, Fischman et al. (2)
showed that the immediate and six-month follow-up
MLD was significantly larger and the incidence of
Table 2. Angiographic Characteristics in Different Treatment Groups
Balloon
Angioplasty
(n 5 169)
Stent
(n 5 117)
Rotational
Atherectomy
(n 5 107)
CABG
(n 5 117)
LAD lesion (%) 47 30* 42 44
Type C lesion (%) 23 23 23 20
Lesion length (mm) 23 6 10 18 6 6* 21 6 5 —
Post-treatment MLD (mm) 3.0 6 0.4 3.3 6 0.4* 2.9 6 0.5 —
Multivessel disease (%) 22 25 20 85*
*p , 0.05 compared with other groups.
CABG 5 coronary artery bypass surgery; LAD 5 left anterior descending; MLD 5 minimal luminal diameter.
Table 3. Incidence of Clinical End Points in Different Treatment Groups
Balloon
Angioplasty
(n 5 169)
Stent
(n 5 117)
Rotational
Atherectomy
(n 5 107)
CABG
(n 5 117)
Angina/MI (%) 32 30 27 23
PCI (%) 17 16 11 7*
TVR (%) 39 40 33 8*
Death (%) 9 6 6 5
MACE (%) 43 40 33 23*
*p , 0.05 compared with balloon angioplasty, stent or rotational atherectomy.
CABG 5 coronary artery bypass graft surgery; MACE 5 major adverse cardiovascular events; MI 5 myocardial infarction;
PCI 5 percutaneous interventions; TVR 5 target vessel revascularization.
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coronary events was significantly less in the stent group
compared with the BA group.
Incidence of ISR. Despite the superiority of stenting, ISR
remains a major limitation to its effectiveness. The incidence
of ISR is variable depending on the definition, and angio-
graphic ISR rates up to 46% and TVR rates up to 30% have
been reported in several studies (1–4).
Predictors and pathophysiology of ISR. Multiple clinical
and angiographic variables have been shown to be associated
with a higher risk of ISR. The most important predictors
seem to be postprocedure MLD, lesion length, LAD lesion,
presence of diabetes, time to ISR and use of multiple stents
(32–36).
Extensive data have shown that ISR is mainly caused by
intimal hyperplasia and, less importantly, by stent elastic recoil.
Animal and postmortem studies reported that the process is
initiated by a giant cell-based inflammatory reaction with
subsequent smooth muscle cell migration and proliferation in
the newly formed intimal layer (37,38). These findings have
been confirmed by angiographic and intravascular ultrasound
studies (24), which showed that the decrease in lumen corre-
lated strongly with the increase in neointimal tissue rather than
the decrease in-stent dimensions.
PTCA versus stenting for ISR. Several studies have
compared the efficacy of different percutaneous techniques
in the treatment of ISR (24–31). When compared with BA,
stenting for ISR may provide better immediate procedural
results. In our study, the postprocedure MLD in the stent
group was significantly larger than it was in the BA group
(3.3 6 0.4 vs. 3.0 6 0.4 mm). Other studies (24,25) have
shown similar results. In the Washington Hospital Center
experience (24), BA recovered only 85% of the minimal
cross-section area of the original stent with 18% residual
stenosis, while stent implantation, on the other hand,
appears to recover all the lumen area of the original
implantation procedure.
Despite better procedural results, patients who undergo
repeat stent seem to have similar long-term outcomes as
those who undergo BA. In our series, the incidence of TVR
and MACE was the same in both groups. Similarly,
Waksman et al. (25) reported a subanalysis of the Wash-
ington Radiation for In-Stent Restenosis Trial (WRIST)
study where the late clinical outcomes of the stent group
were not different from the BA group. In a different study
by Lefevre at al. (26), the seven-month incidence of TVR
was less in the stent group compared with the BA group,
although the difference did not reach statistical significance.
A potential explanation of these findings is the phenome-
non of exaggerated hyperplasia seen with repeat stenting. In
fact, Mintz et al. (39) have shown, using an intravascular
ultrasound study of WRIST patients, that the increase in
intimal hyperplasia area was significantly greater in patients
receiving repeat stent compared with other types of percu-
taneous interventions and that this increase can be neutral-
ized by irradiation therapy.
RA for ISR. Since a major mechanism of ISR is intimal
hyperplasia, then debulking and tissue removal with RA
might provide a theoretical advantage. Animal studies have
shown that intimal hyperplasia is significantly less after RA
compared with BA in a porcine model of ISR (40). Human
studies, on the other hand, have yielded conflicting results
(27–31). In our study, patients who underwent RA tended
to have a better outcome than those who underwent BA or
repeat stent, although the difference was not statistically
significant. Other studies (25,29,30) have shown that RA
and BA are equivalent in the management of ISR. Lauer et
al. (29) reported that the immediate and six-month MLD
was similar in both groups, and Waksman et al. (25)
Table 4. Two-Year Event-Free Survival Rate in Different Treatment Groups
Balloon
Angioplasty
(n 5 169)
Stent
(n 5 117)
Rotational
Atherectomy
(n 5 107)
CABG
(n 5 117)
Angina/MI (%) 65 6 5 66 6 5 64 6 6 72 6 5
TVR (%) 75 6 4 73 6 5 73 6 5 90 6 4*
Death (%) 92 6 3 96 6 2 93 6 3 94 6 3
MACE (%) 55 6 4 57 6 6 58 6 6 66 6 5
*p , 0.05 compared with balloon angioplasty, stent or rotational atherectomy.
CABG 5 coronary artery bypass surgery; MACE 5 major adverse cardiovascular events; MI 5 myocardial infarction;
TVR 5 target vessel revascularization.
Table 5. Incidence of TVR and MACE in Different Treatment Groups According to Diabetes Status
Patients With Diabetes Patients Without Diabetes
Balloon
Angioplasty
(n 5 36)
Stent
(n 5 30)
Rotational
Atherectomy
(n 5 37)
CABG
(n 5 36)
Balloon
Angioplasty
(n5 109)
Stent
(n 5 76)
Rotational
Atherectomy
(n 5 65)
CABG
(n 5 75)
TVR (%) 33 33 22 11 22* 18† 21 7
Death (%) 7 6 5 3 7 7 6 5
MACE (%) 53 53 32 28 40* 38† 34 29
*p , 0.05 compared with diabetics treated with balloon angioplasty; †p , 0.05 compared with diabetics treated with stent.
CABG 5 coronary artery bypass graft surgery; MACE 5 major adverse cardiovascular events; TVR 5 target vessel revascularization.
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reported in the WRIST study that the long-term outcomes
of different percutaneous interventions are the same regard-
less of irradiation use. In a study by Dauerman et al. (27),
28% of patients in the RA group underwent TVR at one
year follow-up compared with 46% in the BA group (p 5
0.18). Lee et al. (28), on the other hand, showed that the
incidence of clinical events at six months was significantly
less in the RA group compared with the BA group (0% vs.
6.7%). Nevertheless, BA was superior to RA in the first
randomized trial for management of ISR (31).
Diabetes and ISR. While acknowledging the small num-
ber of patients with diabetes in our study, several cautious
observations can be made: RA may be particularly useful in
patients with diabetes. Patients with diabetes who under-
went RA had better outcomes than those who underwent
BA or repeat stenting and had similar outcomes as patients
without diabetes who underwent RA. On the other hand,
patients with diabetes who underwent BA or repeat stenting
had worse outcomes than patients without diabetes who had
either of these procedures. This may be due to the fact that
intimal hyperplasia is more exaggerated in patients with
diabetes (41,42) and that tissue debulking with RA might
provide a greater benefit when compared with BA or repeat
stent. For example, Kornowski et al. (41) showed, using a
serial intravascular ultrasound analysis, that in stented le-
sions the decrease in lumen area was less and the increase in
intimal hyperplasia was greater in patients with diabetes
compared to patients without diabetes.
CABG for ISR. Finally, patients with and without diabe-
tes who underwent CABG for treatment of ISR (mainly
because of the presence of multivessel disease) had a
significantly better outcome than those who underwent
percutaneous interventions, mostly in the form of lower
TVR rates. These results are similar to those seen in trials
comparing PTCA and CABG for de novo coronary artery
disease and likely reflect the lower incidence of surgical graft
restenosis.
STUDY LIMITATIONS
The main limitation of this study derives from its nonran-
domized and retrospective nature. Instead, a large consec-
utive group of patients was studied. Classification of ISR
into focal or diffuse types was not done. Angiographic
follow-up was not available on all patients. Additionally, the
analysis of patients with diabetes suffers from all the
limitations inherent in subgroup analysis. For all these
reasons, our results must be considered hypothesis-
generating rather than conclusive.
CONCLUSIONS
Stenting has shown superior short- and long-term outcomes
compared with BA in de novo coronary artery disease.
In-stent restenosis, however, remains a challenging prob-
lem, and the optimal management is yet to be determined.
Despite better procedural results with repeat stenting, the
long-term outcomes seem to be similar to BA, probably
because of exaggerated intimal hyperplasia induced by the
repeat stenting procedure. Tissue debulking with RA might
be particularly useful in patients with diabetes where tissue
intimal hyperplasia is more abundant. In patients with
multiple vessel disease and ISR, CABG seems to yield the
best outcomes. Randomized trials are needed to determine
the best treatment strategy for ISR.
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